Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Liabilities and Shareholders Equity (2020 - 2022)

Historic Liabilities and Shareholders Equity for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q3 2022 value amounting to $686.6 million.

  • Atea Pharmaceuticals' Liabilities and Shareholders Equity fell 1860.43% to $686.6 million in Q3 2022 from the same period last year, while for Dec 2022 it was $2.1 billion, marking a year-over-year decrease of 3696.72%. This contributed to the annual value of $772.9 million for FY2021, which is 1050.68% down from last year.
  • Per Atea Pharmaceuticals' latest filing, its Liabilities and Shareholders Equity stood at $686.6 million for Q3 2022, which was down 1860.43% from $694.3 million recorded in Q2 2022.
  • In the past 5 years, Atea Pharmaceuticals' Liabilities and Shareholders Equity ranged from a high of $871.5 million in Q2 2021 and a low of $110.1 million during Q3 2020
  • In the last 3 years, Atea Pharmaceuticals' Liabilities and Shareholders Equity had a median value of $772.9 million in 2021 and averaged $711.2 million.
  • As far as peak fluctuations go, Atea Pharmaceuticals' Liabilities and Shareholders Equity skyrocketed by 66608.36% in 2021, and later plummeted by 2033.23% in 2022.
  • Quarter analysis of 3 years shows Atea Pharmaceuticals' Liabilities and Shareholders Equity stood at $863.6 million in 2020, then dropped by 10.51% to $772.9 million in 2021, then dropped by 11.17% to $686.6 million in 2022.
  • Its Liabilities and Shareholders Equity stands at $686.6 million for Q3 2022, versus $694.3 million for Q2 2022 and $717.2 million for Q1 2022.